Incyte
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors
- Conditions
- MelanomaColorectal Carcinoma (CRC)Hepatocellular Carcinoma (HCC)Renal Cell Carcinoma (RCC)Microsatellite Instability - High (MSI-H)Mismatch Repair Deficient (dMMR)
- Interventions
- Drug: INCB 99280 with Ipilimumab
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 8
- Registration Number
- NCT05909995
- Locations
- ๐บ๐ธ
Valkyrie Clinical Trials, Los Angeles, California, United States
๐บ๐ธUC Irvine Medical Center, Orange, California, United States
๐บ๐ธSharp Memorial Hospital, San Diego, California, United States
Topical Ruxolitinib Evaluation in Chronic Hand Eczema
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 186
- Registration Number
- NCT05906628
- Locations
- ๐บ๐ธ
Southwest Skin Specialists Phoenix Biltmore, Phoenix, Arizona, United States
๐บ๐ธFirst Oc Dermatology, Fountain Valley, California, United States
๐บ๐ธMarvel Clinical Research Llc, Huntington Beach, California, United States
A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma
- Conditions
- Cutaneous Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2023-06-05
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 63
- Registration Number
- NCT05888844
- Locations
- ๐ฆ๐บ
Border Medical Oncology Research Unit, Albury, New South Wales, Australia
๐ฆ๐บTownsville Cancer Centre, Townsville, Queensland, Australia
๐ฆ๐บPrincess Alexandra Hospital Australia, Woolloongabba, Queensland, Australia
A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 73
- Registration Number
- NCT05879822
- Locations
- ๐ง๐ท
Fundacao Pio Xii Hospital de Cancer de Barretos, Barretos, Brazil
๐ง๐ทCionc-Centro Integrado de Oncologia de Curitiba, Curitiba, Brazil
๐ง๐ทHospital Erasto Gaertner - Liga Paranaense de Combate Ao Cรขncer, Curitiba, Brazil
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma
- Conditions
- Moderate to Severe Asthma
- Interventions
- First Posted Date
- 2023-05-09
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 240
- Registration Number
- NCT05851443
- Locations
- ๐บ๐ธ
Allervie Clinical Research, Birmingham, Alabama, United States
๐บ๐ธKern Allergy Medical Clinic, Inc, Bakersfield, California, United States
๐บ๐ธIntegrated Research of Inland, Inc, Upland, California, United States
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
- Conditions
- Solid TumorsAdvanced Solid TumorsMetastatic Solid Tumors
- Interventions
- First Posted Date
- 2023-05-01
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 408
- Registration Number
- NCT05836324
- Locations
- ๐บ๐ธ
The Angeles Clinic and Research Institute, Los Angeles, California, United States
๐บ๐ธValkyrie Clinical Trials, Los Angeles, California, United States
๐บ๐ธDana Farber Cancer Institute, Boston, Massachusetts, United States
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
- Conditions
- Prurigo Nodularis
- Interventions
- Drug: Vehicle Cream
- First Posted Date
- 2023-03-10
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 190
- Registration Number
- NCT05764161
- Locations
- ๐บ๐ธ
University of Alabama At Birmingham, Birmingham, Alabama, United States
๐บ๐ธNorthwest Arkansas Clinical Trials Center, Arkansas, Arkansas, United States
๐บ๐ธDermatology Research Associates, Los Angeles, California, United States
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
- Conditions
- Prurigo
- Interventions
- Drug: Vehicle Cream
- First Posted Date
- 2023-03-06
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 204
- Registration Number
- NCT05755438
- Locations
- ๐บ๐ธ
Medical Dermatology Specialists Phoenix, Phoenix, Arizona, United States
๐บ๐ธJohnson Dermatology, Fort Smith, Arkansas, United States
๐บ๐ธFirst Oc Dermatology, Fountain Valley, California, United States
A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo
- Conditions
- Nonsegmental Vitiligo With Genital Involvement
- Interventions
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 49
- Registration Number
- NCT05750823
- Locations
- ๐บ๐ธ
Center For Dermatology Clinical Research, Inc, Fremont, California, United States
๐บ๐ธVitiligo & Pigmentation Institute of Southern California, Los Angeles, California, United States
๐บ๐ธHamzavi Dermatology, Fort Gratiot, Michigan, United States
Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD
- Conditions
- Graft-versus-host Disease (GVHD)
- First Posted Date
- 2023-02-10
- Last Posted Date
- 2023-02-10
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT05722912